The angiotensin converting enzyme inhibitors – alternative clinical applications

  • Beata Stanisz Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Poland
  • Katarzyna Regulska Greater Poland Oncology Center
  • Miłosz Regulski Chair and Department of Toxicology, Poznan University of Medical Sciences, Poland
Keywords: renin-angiotensin system, off-label use, cancer


Angiotensin converting enzyme inhibitors have emerged as a useful strategy in the management of hypertension and other cardiovascular system-related diseases. However, a wide range of their biological effects has turned the scientific interest towards other possible clinical applications of these drugs. The present review demonstrates the available data on the reported angiotensin-converting enzyme inhibitors – based therapies in the treatment of the following human disturbances: cancer, obesity, Barrett syndrome, erythrocytosis, a high-dose-chemotherapy-induced cardiotoxicity, Marfan syndrome, Duchenne muscular dystrophy, migraine, Raynaud’s syndrome and Alzheimer disease.


Regulska K, Stanisz B, Regulski M. The Renin-Angiotensin system as a target of novel anticancer therapy. Curr Pharm Des. 2013 Dec; 19(40):7103–25.

Paszun S, Stanisz B. Rys historyczny – nadciśnienie tętnicze, układ renina–angiotensyna i synteza pierwszego inhibitora enzymu konwertującego angiotensynę. Journal of Medical Science. 2008; 5(77):392–8.

Brown NJ, Vaughan DE. Angiotensin-Converting Enzyme Inhibitors. Circulation. 1998 Apr; 97 (14):1411–20.

Sica DA. The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point. Curr Hypertens Rep. 2010 Apr;12(2):67–73.

Oko A. Przydatność leków inhibitorów konwertazy angiotensyny i antagonistów wapnia w zapobieganiu postępującemu uszkodzeniu nerek. Journal of Medical Science. 1999; 5(68):467–76.

Attoub S, Gaben AM, Al-Salam S, Al Sultan MA, John A, Nicholls MG, Mester J, Petroianu G. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann NY Acad Sci. 2008 Sep; 1138:65–72.

Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer. 1998 Mar; 77(6):880–3.

Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med. 1991 Mar; 196(3):280–3.

Haznedaroglu IC, Beyazit Y. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. Renin Angiotensin Aldosterone Syst. 2010 Dec; 11(4):205–13.

Yamamoto D,, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol. 2007 Dec;43(6):670–6.

Kuntze LB, Antonio RC, Izidoro-Toledo TC, Meschiari CA, Tanus-Santos JE, Gerlach RF. Captopril and Lisinopril Only Inhibit Matrix Metalloproteinase-2 (MMP-2) Activity at Millimolar Concentrations. Basic Clin Pharmacol Toxicol. 2014 Mar; 114(3):233–9.

Cortez-Retamozo V, Etzrodt M, Newton A et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity. 2013 Feb; 38(2):296–308.

Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinumbased chemotherapy. J Cancer Res Clin Oncol. 2009 Oct; 135(10):1429–35.

Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW, Kim YH. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 2012 Oct; 83(6):354–60.

Yuge K, Miyajima A, Tanaka N, Shirotake S, Kosaka T, Kikuchi E, Oya M. Prognostic value of reninangiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol. 2012 Nov; 19(12):3987–93.

Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007 Oct;10(10A):1151–5.

Velkoska E, Warner FJ, Cole TJ, Smith I, Morris MJ. Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat. Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):49–55.

Premaratna SD, Manickam E, Begg DP, Rayment DJ, Hafandi A, Jois M, Cameron-Smith D, Weisinger RS. Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice. Int J Obes (Lond). 2012 Feb;36(2):233–43.

Santos EL, de Picoli Souza K, Guimaraes PB, Reis FC, Silva SM, Costa-Neto CM, Luz J, Pesquero JB. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol. 2008 Feb;8(2):247–53.

Dondi M, Fanti S, Monetti N.J. Bartter's syndrome: renal scintigraphic appearance after captopril administration. Nucl Med. 1996 Oct;37(10):1688–90.

T. Suzuki, M. Nangaku, S. Oku, H. Takemura, Y. Yokoyama, Y. Takahashi, T. Fujita. Captopril renography in Bartter's syndrome. Clin Exp Nephrol. 2002 Sep;6(3):0163–0165.

Colamussi P, Panareo S, Cittanti C, Giganti M, Filice A, Baresic T, El Maoued S, Rizzati R, Piffanelli A. Bartter's syndrome and captopril scintigraphy: a case report. Ann Nucl Med. 2003 Apr;17(2):149–52.

Hené RJ, Koomans HA, Dorhout Mees EJ, vd Stolpe A, Verhoef GE, Boer P. Correction of hypokalemia in Bartter's syndrome by enalapril. Am J Kidney Dis. 1987 Mar;9(3):200–5.

Leshem-Rubinow E, Steinvil A, Zeltser D, Berliner S, Rogowski O, Raz R, Chodick G, Shalev V. Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Mayo Clin Proc. 2012 Dec;87(12):1189–95.

Dietz HC, Loeys B, Carta L, Ramirez F. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet. 2005 Nov;139C(1):4–9.

Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007 Oct 3;298(13):1539–47.

Mendell JR, Sahenk Z, Prior TW. The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability. J Child Neurol. 1995 Mar;10(2):150–9.

Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009 Feb;53(1):72–8.

Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol. 2012 Jul;110(1):98–102.

Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, Berard C, Vaksmann G, Weber S, Bécane HM. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J. 2007 Sep;154(3):596–602.

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 Dec; 5(23):2474–81.

Kalam K, Marwic TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. EJC. 2013 Sep;49(13):2900–9.

Blaes AH, Gaillard P, Peterson BA, Yee D, Virnig B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat. 2010 Jul;122(2):585–90.

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F and on behalf of the ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23(suppl 7):vii155-vii166.

Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache. 1995 Sep;35(8):470–1.

Schrader H, Stovner LJ, Helde G, T Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001 Jan;322(7277):19.

Challenor VF. Drugs. Angiotensin converting enzyme inhibitors in Raynaud's phenomenon. 1994 Dec;48(6):864–7.

Miyazaki S, Miura K, Kasai Y, Abe K, Yoshinaga K. Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon. Br Med J (Clin Res Ed). 1982 Jan;30(6312):310–11.

Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon. Br J Clin Pharmacol. 1991 Apr;31(4):477–80.

Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006 Nov;40(11):1998–2002.

Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, Rolland Y, Vellas B. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort. J Am Geriatr Soc. 2013 Sep;61(9):1482–8.

How to Cite
Stanisz, B., Regulska, K., & Regulski, M. (2016). The angiotensin converting enzyme inhibitors – alternative clinical applications. Journal of Medical Science, 83(1), 57-61. Retrieved from
Review Papers